Clinical Trial Update: Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1b/2 neoadjuvant trial evaluating the combination of domatinostat, nivolumab, and ipilimumab in stage III cutaneous or unknown primary melan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Domatinostat (domatinostat)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Malignant Melanoma Stage III | Phase 1, Phase 2 | Status: COMPLETED